Hong Kong – Mabpharm Limited (MABPHARM-B) filed its Monthly Return for Equity Issuer for the period ended 31 August 2026, confirming a stable capital structure and continued compliance with Hong Kong’s public float requirements.

Authorised and Registered Capital • Total authorised share capital stayed unchanged at USD 5.00 million, representing 50.00 billion ordinary shares with a par value of USD 0.0001 each.

Issued Shares and Treasury Position • Issued share count remained at 4.12 billion ordinary shares, with zero treasury shares on record. • No new shares were issued, repurchased, or cancelled during the month.

Public Float Compliance • The company affirmed that it met the Main Board’s minimum 25% public float threshold as at 31 August 2026.

Equity Incentives • The Share Option Scheme, approved on 10 August 2018, reported 72.67 million outstanding options at month-end—unchanged from July. • No options were exercised, and no shares were issued or transferred under equity-linked instruments.

Capital Instruments • The company had no outstanding warrants, convertibles, or other share-issuance arrangements during the reporting period.

Governance • The monthly return was submitted by Secretary Tsang Ho Yin on 3 September 2026, fulfilling disclosure obligations under Hong Kong Listing Rules.

Key Takeaway MABPHARM-B’s August filing highlights a period of capital stability, with no dilution events and full adherence to public float requirements, positioning the company on solid regulatory footing as it heads into the final quarter of 2026.